• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • ObGyn
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • ObGyn
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

    Thumbnail
    View/ Open
    Endometrial carcinoma chemosensitivity testing.pdf (243.5Kb)

    Show full item record
    
    Author
    Ballard, Karen S.; Homesley, Howard D.; Hodson, Charles; Presant, Cary A.; Rutledge, James; Hallquist, Allan; Perree, Mathieu
    Abstract
    Objective: The in vitro microculture kinetic (MiCK) apoptosis assay has been used to predict single or combination chemotherapy response in leukemia patients. This feasibility study addressed MiCK in endometrial cancer specimens. Methods: Endometrial cancer specimens from total abdominal hysterectomies were processed at a central laboratory. Single cell suspensions of viable endometrial cancer cells were plated in individual wells. Single and combination regimens were tested: combinations of doxorubicin, cisplatin, and paclitaxel and carboplatin and paclitaxel (Gynecologic Oncology Group [GOG] 209 endometrial cancer phase III trial arms) as well as single agent testing with paclitaxel, carboplatin, doxorubicin, cisplatin, ifosfamide, and vincristine (active agents in GOG trials). Apoptosis was measured continuously over 48 hours. Results: Fifteen of nineteen patients had successful assays. The highest mean chemo sensitivity was noted in the combination of cisplatin, doxorubicin, and paclitaxel with lower mean chemosensitivity for carboplatin and paclitaxel. Combination chemotherapy had higher chemosensitivity than single drug chemotherapy. However, in 25% of patients a single drug had higher chemosensitivity than combination chemotherapy. As single agents, ifosfamide, cisplatin, and paclitaxel had the highest kinetic unit values. Conclusion: Using a panel of agents simulating clinical dose regimens, the MiCK assay was feasible in evaluating in vitro chemosensitivity of endometrial cancer. MiCK assay results correlated with GOG clinical trial results. However, 25% of patients might be best treated with single agent chemotherapy selected by MiCK. Ifosfamide, cisplatin, and paclitaxel appear to have high activity as single agents. MiCK may be useful in future new drug testing and individualizing endometrial cancer patient’s chemotherapy management. Originally published Journal of Gynecologic Oncology, Vol. 21, No. 1, Mar 2010
    URI
    http://hdl.handle.net/10342/3215
    Subject
     Chemosensitivity assay; Chemotherapy; Endometrial cancer 
    Date
    2010-03
    Citation:
    APA:
    Ballard, Karen S., & Homesley, Howard D., & Hodson, Charles, & Presant, Cary A., & Rutledge, James, & Hallquist, Allan, & Perree, Mathieu. (March 2010). Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. Journal of Gynecologic Oncology, (21:1), p.45-49. Retrieved from http://hdl.handle.net/10342/3215

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Ballard, Karen S., and Homesley, Howard D., and Hodson, Charles, and Presant, Cary A., and Rutledge, James, and Hallquist, Allan, and Perree, Mathieu. "Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment". Journal of Gynecologic Oncology. 21:1. (45-49.), March 2010. April 23, 2021. http://hdl.handle.net/10342/3215.
    Chicago:
    Ballard, Karen S. and Homesley, Howard D. and Hodson, Charles and Presant, Cary A. and Rutledge, James and Hallquist, Allan and Perree, Mathieu, "Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment," Journal of Gynecologic Oncology 21, no. 1 (March 2010), http://hdl.handle.net/10342/3215 (accessed April 23, 2021).
    AMA:
    Ballard, Karen S., Homesley, Howard D., Hodson, Charles, Presant, Cary A., Rutledge, James, Hallquist, Allan, Perree, Mathieu. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. Journal of Gynecologic Oncology. March 2010; 21(1) 45-49. http://hdl.handle.net/10342/3215. Accessed April 23, 2021.
    Collections
    • ObGyn
    Publisher
    East Carolina University

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback